Ronit Harpaz co-founder and CEO of Endoron (company pic)
Endoron is an Israeli medtech startup specializing in endograft stapling solutions for endovascular repair of abdominal aortic aneurysms. The firm closed its $10 million Series A funding round led by Sofinnova Partners.
Endoron’s innovative stapling device tackles the problems of sealing and keeping endografts in place, especially in complex cases. This technology ensures a tight seal and secure attachment of the endograft, preventing leaks and the need for high-risk open surgery in the long run.
Abdominal aortic aneurysms (AAAs) are a weakening and bulging of the aorta, the main artery that carries blood from your heart down to the rest of your body.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
They most often occur in the part of the aorta that runs through your abdomen (belly). AAAs usually grow slowly and don’t cause any symptoms. But a ruptured AAA is a life-threatening medical emergency.
Founded in 2019, Endoron Medical was established by a team of experts with extensive industry expertise and entrepreneurial experience. The founding team includes Ronit Harpaz, an Elite 8400 member and former CEO of Bendit Technologies; Prof. Ron Karmeli, a world-renowned vascular surgeon; and Eyal Teichman, a mechanical engineer with over 30 years of R&D experience. Together, they are committed to advancing endovascular repair solutions to improve patient outcomes.
Endograft stapling solutions are a new frontier in the minimally invasive repair of abdominal aortic aneurysms (AAAs). These solutions aim to address the challenges associated with traditional endografts, which can sometimes migrate or leak over time.
A thin, tube-like device called an endograft is inserted into the weakened area of the aorta through a small incision in the groin. A catheter-based stapler is then used to secure the endograft in place. This stapling mechanism creates a tight seal between the endograft and the aortic wall, preventing blood from leaking around the device.
Endograft stapling is still under development. Endoron Medical, a medical technology company, is one pioneer in this field with their Aortoseal device currently undergoing clinical trials.
“Sofinnova Partners are the go-to investors within medtech. They bring a wealth of operational experience working with high-growth companies like ours,” said Ronit Harpaz, co-founder and CEO of Endoron. “With their continued support, I am confident we will reach key clinical and regulatory milestones as we advance our EndoStapling technology towards the clinic. The EIC’s participation further solidifies our commitment to bringing this innovative solution to the European market.”
